
The study presents preliminary safety and efficacy data from the initial roll‐in cohort of the REBALANCE‐HF trial. The open‐label (roll‐in) arm of REBALANCE‐HF will enrol up to 30 patients, followed by the randomized, sham‐controlled portion of the trial. The preliminary open‐label results from the multicentre REBALANCE‐HF roll‐in cohort support the safety and efficacy of SAVM in HFpEF. However, the findings require confirmation in the trial's ongoing randomized, sham‐controlled portion.
Like
Save
Share